Table 1. Comparison of clinicopathological data among groups of IPNG and IPNB.
| IPNG | IPNB | P value | |||||
|---|---|---|---|---|---|---|---|
| IPNG-1 | IPNG-2 | P value | IPNB-1 | IPNB-2 | P value | ||
| Demographic | |||||||
| Age (year) | 56.5 ± 16.9 | 65.8 ± 17.2 | 0.135 | 59.7 ± 1 1.5 | 56.1 ± 12.7 | 0.445 | 0.261 |
| Gender (M:F) | 8:7 | 6:11 | 0.476 | 6:4 | 11:11 | 0.712 | 0.453 |
| Symptoms | |||||||
| Abdominal pain | 8/15§ | 8/17 | 1.000 | 5/10§ | 7/22 | 0.438 | 0.313 |
| Jaundice | 1/15 | 2/17 | 1.000 | 4/10 | 16/22 | 0.119 | < 0.001 |
| Fever | 2/15 | 3/17 | 1.000 | 4/10 | 5/22 | 0.407 | 0.226 |
| Weight loss | 3/15 | 6/17 | 0.444 | 5/10 | 12/22 | 1.000 | 0.042 |
| Biliary stones | 7/15 | 6/17 | 0.720 | 3/10 | 1/22 | 0.079 | 0.011 |
| Liver function tests | |||||||
| ALT | 1/15 | 2/16 | 1.000 | 5/10 | 17/22 | 0.217 | < 0.001 |
| TBil | 1/15 | 3/16 | 0.600 | 6/10 | 14/22 | 1.000 | < 0.001 |
| DBil | 1/15 | 2/16 | 1.000 | 5/10 | 15/22 | 0.438 | < 0.001 |
| GGT | 4/15 | 3/16 | 0.685 | 6/10 | 20/22 | 0.060 | < 0.001 |
| ALP | 1/15 | 2/16 | 1.000 | 6/10 | 15/22 | 0.703 | < 0.001 |
| Tumor markers | |||||||
| CEA | 0/7 | 4/13 | 0.249 | 1/10 | 4/22 | 1.000 | 0.977 |
| CA19-9 | 2/7 | 2/14 | 0.574 | 5/10 | 15/21 | 0.423 | 0.001 |
| Pathological features | |||||||
| Multiple lesions (≥ 2) | 4/15 | 5/17 | 1.000 | 2/10 | 4/22 | 1.000 | 0.376 |
| Size (cm) | 1.5 ± 1.2 | 4.0 ± 2.2 | < 0.001 | 2.3 ± 1.3 | 2.3 ± 1.1 | 0.944 | 0.231 |
| Lymphatic metastasis | 1/14 | 4/17 | 0.344 | 0/10 | 4/21 | 0.227 | 1.000 |
| Positive margin | 0/15 | 3/17 | 0.229 | 0/10 | 5/22 | 0.155 | 0.705 |
| Histological subtype | 1.000 | 0.019 | 0.923 | ||||
| Pancreaticobiliary | 5/12 | 7/15 | 7/9 | 4/16 | |||
| Intestinal | 6/12 | 7/15 | 1/9 | 10/16 | |||
| Oncocytic | 1/12 | 1/15 | 1/9 | 2/16 | |||
| Gastric | 0/12 | 0/15 | 0/9 | 0/16 | |||
Note. §Number of positive cases /total number of cases with available data.
Abbreviations: ALT, alanine aminotransferase; TBil, total bilirubin; DBil, direct bilirubin; GGT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.